Chlamydia infections remain a worldwide issue that impacts human and animal populations. Our company provides assistance for chlamydia infection vaccine as well as therapeutics development by providing a range of services.
Overview of Chlamydia Infection
Chlamydia is a common STI caused by the intracellular bacteria of the Chlamydia genus. Two of the most noticeable species exposing humans are Chlamydia trachomatis and Chlamydia pneumoniae. These bacteria are capable of causing a variety of clinical manifestations, starting from genitourinary and respiratory infections and extending to appendicitis, pelvic inflammatory disease, infertility, and pneumonia, among other clinical.
Fig. 1 Immune response processes during genital Chlamydia infection in mice. (Dockterman J., et al., 2021)
Vaccine Development for Chlamydia Infection
Creating a set of effective vaccines to chlamydia, which targets the pathogen, has been a major challenge, given the distinctive biology of the pathogen and its means of immune evasion. Such challenges render researchers' systematic attempts to employ different vaccine devices such as whole-cell, subunit and live-attenuated strategies to optimize the most unlikely ones.
The vaccine has been able to induce strong and persistent both humoral and cellular responses against etiological agents while simultaneously reducing the disease severity and pathogen load in this ecologically important host cross, which, coupled with other possible profiting features, made it possible to develop a multivalent recombinant rMOMP vaccine against C. pecorum koalas infections.
Therapeutics Development for Chlamydia Infection
Antibiotics like doxycycline, azithromycin, and erythromycin have been the first line solution for chlamydia infections. Lately however, antibiotic resistance has been a growing concern so there is a need to develop more effective and focused therapies along with alternate antimicrobial agents.
Table 1. Minimum inhibitory concentration (MIC) of selected antimicrobial agents against C. trachomatis and C. pneumoniae. (Kohlhoff S. A., et al., 2015)
| Antimicrobial |
C.trachomatis-MIC (µg/ml) |
C.pneumoniae-MIC (µg/ml) |
| Approved drugs |
| Doxycycline |
0.031-0.25 |
0.015-0.5 |
| Tigecycline |
0.03-0.125 |
0.125-0.25 |
| Erythromycin |
0.016-2 |
0.015-0.25 |
| Azithromycin |
0.6-2 |
0.05-0.25 |
| Clarithromycin |
0.015-0.125 |
0.004-0.125 |
| Clindamycin |
2-16 |
- |
| Ciprofloxacin |
0.5-2 |
1-4 |
| Levofloxacin |
0.12-0.5 |
0.25-1 |
| Moxifloxacin |
0.5-1 |
0.125-1 |
| Rifampin |
0.005-0.25 |
0.0075-0.03 |
| Trimethoprim |
≥128 |
≥128 |
| Sulfamethoxazole |
0.5-4 |
≥500 |
| Gentamicin |
500 |
500 |
| Vancomycin |
1000 |
1000 |
| Investigational drugs |
| Solithromycin (CEM-101) |
0.125-0.5 |
0.25-1 |
| Sitafloxacin |
0.031-0.063 |
0.031-0.125 |
| Nemonoxacin |
0.03-0.125 |
0.03-0.125 |
| Delafloxacin |
- |
0.06-0.125 |
| AZD0914 |
0.06-0.5 |
0.25-1 |
| Rifalazil |
0.00125-0.0025 |
0.00125 |
Our Services
We at the firm are committed towards winning the battle against Chlamydia infections through development of chlamydia vaccine and therapy. Our team comprising of their skilled scientists, immunologists, microbiologists, and drug discovery specialists works in high coordination towards the goal of providing complete solutions for the clients.
- Mouse Models (C.muridarum)
- Guinea Pig Models (C.caviae)
- Non-Human Primate (NHP) Models
- Pig-Tailed Macaque Models
- Baboon Models (Papio anubis)
- Human chlamydia trachomatis in Mice
If you are an entrepreneur with a focus in biotechnologies, working at a research facility, or run a pharmaceutical company that focuses on or deals with Chlamydia-related projects, we can partner with you throughout the process – right from targeting and candidate searching to preclinical validation. Our in-house specialists provide exceptionally reliable information and data to hasten Chlamydia cure development. For more information about our services and a technical quote, we would be happy to help you eager to undertake a project with us? Then do let us know!
References
- Dockterman Jacob, and Jörn Coers. "Immunopathogenesis of genital Chlamydia infection: insights from mouse models." Pathogens and Disease 79.4 (2021): ftab012.
- Kohlhoff, Stephan A., and Margaret R. Hammerschlag. "Treatment of Chlamydial infections: 2014 update." Expert opinion on pharmacotherapy 16.2 (2015): 205-212.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
